-

02:00:43 PM

ACHFF Stock News

ACHFF - Arch Biopartners Inc.

09/22/23 7:00 AM

OTC : ACHFF

clinical trial

Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that it has submitted applications to the Ministry of Health (MoH) and local Ethics Committee in Turkey to obtain permission to proceed with a Phase II

RHEA-AI

negative

06/27/23 7:15 AM

OTC : ACHFF

clinical trial

Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial

Approval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated acute kidney injury (CS-AKI) LSALT peptide targets dipeptidase-1 (DPEP-1), an enzyme known to mediate organ inflammation in the lungs, liver and kidneys There are currently no treatments available

RHEA-AI

negative

04/18/23 7:10 AM

OTC : ACHFF

Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide

Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that it has safely increased the maximum

RHEA-AI

neutral

03/23/23 7:00 AM

OTC : ACHFF

Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program

Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that Arch is receiving advisory services and

RHEA-AI

neutral

02/07/23 7:05 AM

OTC : ACHFF

Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease

Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammation, announced that an Arch

RHEA-AI

very positive

10/05/22 7:20 AM

OTC : ACHFF

Arch Biopartners Adds Farris Smith as a Strategic Advisor

Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammation, welcomed Mr. Farris Smith of

RHEA-AI

very positive

08/05/22 7:30 AM

OTC : ACHFF

clinical trial

Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company targeting acute organ inflammation with novel therapeutics, announced today that the Company has added Dr. David Luke as a Strategic Advisor

RHEA-AI

neutral

02/14/22 7:30 AM

OTC : ACHFF

covid-19

Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

Arch Biopartners Inc. (“Arch

RHEA-AI

neutral

02/03/22 7:30 AM

OTC : ACHFF

Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney Injury

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Daniel Muruve at the University of Calgary, and their collaborators, have published a paper in the journal Science

RHEA-AI

neutral

01/04/22 7:25 AM

OTC : ACHFF

covid-19

Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)

Arch Biopartners Inc. (“Arch

RHEA-AI

neutral